

BIO, PhRMA Ask Fed. Circ. to Revisit Double-Patent Ruling

PUBLICATIONS | LESS THAN 1 MIN READ

July 14, 2014


By: Aaron Vehling

Law360

Axinn associate Thomas Hedemann, who represents Natco, was mentioned in Aaron Vehling's article, "BIO, PhRMA Ask Fed. Circ. to Revisit Double-Patent Ruling," which appeared on *Law360*.

Click [here](#) to access the article. A subscription is required.

Related People



Thomas K. Hedemann

To subscribe to our publications, [click here](#).

Featured Insights

- GCR Live: Law Leaders Europe 2025
SPEAKING ENGAGEMENT ANTITRUST
- AHLA Annual Meeting 2025
SPEAKING ENGAGEMENT ANTITRUST
- SABA North America Annual Conference 2025
SPEAKING ENGAGEMENT ANTITRUST
- Navigating Compliance: How the 2025 Hart-Scott-Rodino Updates Are Impacting Businesses
WEBINAR ANTITRUST
- Volunteer Lawyers for the Arts – Champions of the Arts Awards and Gala 2025
SPONSORSHIP ANTITRUST
- NJSBA Annual Meeting and Convention 2025
SPEAKING ENGAGEMENT INTELLECTUAL PROPERTY
- Cost-Effective and Efficient IP Litigation Strategies – Making Paragraph IV Litigation Work for You
WEBINAR INTELLECTUAL PROPERTY
- Hartford HealthCare Black and Red Gala 2025
SPONSORSHIP ANTITRUST
- Informa CompLaw Antitrust West Coast Conference 2025
SPEAKING ENGAGEMENT ANTITRUST
- Recent Decision Shows the Heavy Burden of Actual Malice in Defamation Suits
AXINN VIEWPOINTS LITIGATION & TRIALS

